rs878853922
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_001042492.3(NF1):c.889-2A>G variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 32)
Consequence
NF1
NM_001042492.3 splice_acceptor, intron
NM_001042492.3 splice_acceptor, intron
Scores
5
1
1
Splicing: ADA: 1.000
2
Clinical Significance
Conservation
PhyloP100: 8.58
Genes affected
NF1 (HGNC:7765): (neurofibromin 1) This gene product appears to function as a negative regulator of the ras signal transduction pathway. Mutations in this gene have been linked to neurofibromatosis type 1, juvenile myelomonocytic leukemia and Watson syndrome. The mRNA for this gene is subject to RNA editing (CGA>UGA->Arg1306Term) resulting in premature translation termination. Alternatively spliced transcript variants encoding different isoforms have also been described for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Splicing +-2 bp (donor or acceptor) variant, product NOT destroyed by NMD, known LOF gene, truncates exone, which is 0.020305164 fraction of the gene. No cryptic splice site detected. Exon removal is inframe change.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 17-31200420-A-G is Pathogenic according to our data. Variant chr17-31200420-A-G is described in ClinVar as [Pathogenic]. Clinvar id is 237610.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr17-31200420-A-G is described in Lovd as [Pathogenic]. Variant chr17-31200420-A-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NF1 | NM_001042492.3 | c.889-2A>G | splice_acceptor_variant, intron_variant | ENST00000358273.9 | NP_001035957.1 | |||
NF1 | NM_000267.3 | c.889-2A>G | splice_acceptor_variant, intron_variant | NP_000258.1 | ||||
NF1 | NM_001128147.3 | c.889-2A>G | splice_acceptor_variant, intron_variant | NP_001121619.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NF1 | ENST00000358273.9 | c.889-2A>G | splice_acceptor_variant, intron_variant | 1 | NM_001042492.3 | ENSP00000351015.4 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Cov.: 31
GnomAD4 exome
Cov.:
31
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Neurofibromatosis, type 1 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | NHS Central & South Genomic Laboratory Hub | Nov 19, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 10, 2024 | This sequence change affects an acceptor splice site in intron 8 of the NF1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in a shortened protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with neurofibromatosis type 1 (PMID: 10076878, 30308447, 31730495). In at least one individual the variant was observed to be de novo. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 237610). Studies have shown that disruption of this splice site results in skipping of exon 9, but is expected to preserve the integrity of the reading-frame (PMID: 10076878, 18546366). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Oct 09, 2018 | The variant disrupts a canonical splice site, and is therefore predicted to significantly disrupt the protein structure. Found in at least one symptomatic patient, and not found in general population data. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 25, 2022 | Intronic variant predicted to result in an in-frame deletion of exon 9 and has been confirmed via RT-PCR (Klose 1999, Pros 2008, Xu 2014); Deletions involving coding exons of this gene are a known mechanism of disease (HGMD); Not observed in large population cohorts (gnomAD); Also known as IVS6-2A>G; This variant is associated with the following publications: (PMID: 25525159, 24789688, 10076878, 30530636, 30308447, 31730495, 22155606, 14722917, 10712197, 18546366, 21280148, 26969325) - |
not specified Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Dec 04, 2018 | The NF1 c.889-2A>G variant (rs878853922) is reported in the literature in multiple individuals affected with neurofibromatosis type 1 (Klose 1999, Messiaen 2011, Xu 2014). This variant is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 237610), and is absent from general population databases (1000 Genomes Project, Exome Variant Server, and Genome Aggregation Database), indicating it is not a common polymorphism. This variant disrupts the canonical splice acceptor site of intron 8, which is likely to disrupt gene function, and in vitro functional analyses demonstrate skipping of exon 7 (Klose 1999, Pros 2008, Xu 2014). Based on available information, the c.889-2A>G variant is considered to be pathogenic. References: Klose A et al. Two independent mutations in a family with neurofibromatosis type 1 (NF1). Am J Med Genet. 1999 Mar 5;83(1):6-12. Messiaen L et al. Mosaic type-1 NF1 microdeletions as a cause of both generalized and segmental neurofibromatosis type-1 (NF1). Hum Mutat. 2011 Feb;32(2):213-9. Pros E et al. Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations. Hum Mutat. 2008 Sep;29(9):E173-93. Xu W et al. Fifty-four novel mutations in the NF1 gene and integrated analyses of the mutations that modulate splicing. Int J Mol Med. 2014 Jul;34(1):53-60. - |
NF1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 24, 2024 | The NF1 c.889-2A>G variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. This variant has been reported in multiple individuals with neurofibromatosis type 1 (NF1) (Klose et al. 1999. PubMed ID: 10076878; Tsipi et al. 2018. PubMed ID: 30308447; Table S1 – Assunto et al. 2019. PubMed ID: 31730495), including one individual with NF1 and breast cancer (Frayling et al. 2019. PubMed ID: 30530636). In one individual the variant was reported to be de novo (Tsipi et al. 2018. PubMed ID: 30308447). Functional studies demonstrated this variant results in exon skipping (Klose et al. 1999. PubMed ID: 10076878). Variants that disrupt the consensus splice acceptor site in NF1 are expected to be pathogenic and multiple nucleotide substitutions affecting this splice site (c.889-2A>C, c.889-1G>A) have been reported in individuals with NF1 (Pros et al. 2008. PubMed ID: 18546366; Xu et al. 2014. PubMed ID: 24789688). This variant has not been reported in a large population database, indicating this variant is rare. In ClinVar, nearly all labs have interpreted this variant as pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/237610/). This variant is interpreted as pathogenic. - |
Neurofibromatosis, type 1;C0349639:Juvenile myelomonocytic leukemia;C0553586:Café-au-lait macules with pulmonary stenosis;C1834235:Neurofibromatosis, familial spinal;C2931482:Neurofibromatosis-Noonan syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Juno Genomics, Hangzhou Juno Genomics, Inc | - | PM2_Supporting+PVS1_Strong+PS4_Moderate+PM6+PP4+PP1 - |
Juvenile myelomonocytic leukemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Dec 02, 2022 | - - |
Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 22, 2018 | The c.889-2A>G intronic pathogenic mutation results from an A to G substitution two nucleotides upstream from coding exon 9 in the NF1 gene. This mutation has been identified in multiple individuals and families with neurofibromatosis type 1 (NF1), and has been shown via RT-PCR studies to cause aberrant splicing leading to the skipping of exon 7 (coding exon 9) (Klose A et al. Am. J. Med. Genet., 1999 Mar;83:6-12; Pros E et al. Hum. Mutat., 2008 Sep;29:E173-93; Messiaen L et al. Hum. Mutat., 2011 Feb;32:213-9; Xu W et al. Int. J. Mol. Med., 2014 Jul;34:53-60). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AL_spliceai
Position offset: 2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at